Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF | Zendy

Alice M. Jackson | Zendy; Pooja Dewan | Zendy; Inder S. Anand | Zendy; Jan Bělohlávek | Zendy; Olof Bengtsson | Zendy; Rudolf A. de Boer | Zendy; Michael Böhm | Zendy; David W. Boulton | Zendy; Vijay Chopra | Zendy; David L. DeMets | Zendy; Kieran F. Docherty | Zendy; Andrej Dukát | Zendy; Peter J. Greasley | Zendy; Jonathan G. Howlett | Zendy; Silvio E. Inzucchi | Zendy; Tzvetana Katova | Zendy; Lars Køber | Zendy; Mikhail Kosiborod | Zendy; Anna Maria Langkilde | Zendy; Daniel Lindholm | Zendy; Charlotta Ljungman | Zendy; Felipe A. Martínez | Zendy; Eileen O’Meara | Zendy; Marc S. Sabatine | Zendy; Mikaela Sjöstrand | Zendy; Scott D. Solomon | Zendy; Sergey Tereshchenko | Zendy; Subodh Verma | Zendy; Pardeep S. Jhund | Zendy; John J.V. McMurray | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

Author(s) -

Alice M. Jackson,

Pooja Dewan,

Inder S. Anand,

Jan Bělohlávek,

Olof Bengtsson,

Rudolf A. de Boer,

Michael Böhm,

David W. Boulton,

Vijay Chopra,

David L. DeMets,

Kieran F. Docherty,

Andrej Dukát,

Peter J. Greasley,

Jonathan G. Howlett,

Silvio E. Inzucchi,

Tzvetana Katova,

Lars Køber,

Mikhail Kosiborod,

Anna Maria Langkilde,

Daniel Lindholm,

Charlotta Ljungman,

Felipe A. Martínez,

Eileen O’Meara,

Marc S. Sabatine,

Mikaela Sjöstrand,

Scott D. Solomon,

Sergey Tereshchenko,

Subodh Verma,

Pardeep S. Jhund,

John J.V. McMurray

Publication year - 2020

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.047077

Subject(s) - dapagliflozin , diuretic , medicine , heart failure , tolerability , loop diuretic , ejection fraction , hazard ratio , furosemide , clinical endpoint , placebo , cardiology , adverse effect , randomized controlled trial , endocrinology , diabetes mellitus , confidence interval , type 2 diabetes , alternative medicine , pathology

In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of worsening heart failure and death in patients with heart failure and reduced ejection fraction. We examined the efficacy and tolerability of dapagliflozin in relation to background diuretic treatment and change in diuretic therapy after randomization to dapagliflozin or placebo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research